X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC PHARMA Fact Sheet, ALEMBIC PHARMA Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA Fact Sheet   (APLL)

Here is the latest financial fact sheet of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA quarterly results and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

ALEMBIC PHARMA Price History

Price Rs 513.8
Mkt Cap Rs m 96,852
Vol '000 1.4
P/E X 23.0
P/CF X 12.2
EPS (TTM) Rs 22.3
% ch % -0.5
No. of shares m 188.52
% ch week % -4.0
% ch 1-mth % 2.6
% ch 12-mth % -5.4
52 week H/L Rs 588.0/412.4
(As on Jul 19, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ALEMBIC PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
ALEMBIC PHARMA EQUITY SHARE DATA
High Rs51113310495792 
Low Rs3448103228443 
Sales per share (Unadj.) Rs77.780.698.8109.1167.0 
Earnings per share (Unadj.) Rs6.98.812.515.038.2 
Diluted earnings per shareRs6.98.812.515.038.2 
Cash flow per share (Unadj.) Rs8.710.614.617.442.0 
Dividends per share (Unadj.) Rs1.402.503.003.504.00 
Adj. dividends per shareRs1.402.503.003.504.00 
Dividend yield (eoy) %3.33.11.51.00.6 
Book value per share (Unadj.) Rs21.026.735.846.984.9 
Adj. book value per shareRs21.026.735.846.984.9 
Shares outstanding (eoy) m188.52188.52188.52188.52188.52 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.51.02.13.33.7 
Avg P/E ratio x6.29.116.524.116.2 
P/CF ratio (eoy) x4.97.614.120.814.7 
Price / Book Value ratio x2.03.05.87.77.3 
Dividend payout %20.328.524.023.310.5 
Avg Mkt Cap Rs m8,01215,11938,93968,122116,383 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,6851,9382,4703,0684,214 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
ALEMBIC PHARMA INCOME DATA
Net Sales Rs m14,65415,20418,63220,56131,487 
Other income Rs m1439322355 
Total revenues Rs m14,66815,24318,66420,58431,542 
Gross profit Rs m2,1942,5203,5774,03010,060 
Depreciation Rs m337350405444722 
Interest Rs m262146981837 
Profit before tax Rs m1,6102,0643,1063,5919,356 
Minority Interest Rs m00000 
Prior Period Items Rs m0002-2 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3094117517642,160 
Profit after tax Rs m1,3011,6532,3552,8297,194 
Gross profit margin %15.016.619.219.631.9 
Effective tax rate %19.219.924.221.323.1 
Net profit margin %8.910.912.613.822.8 
ALEMBIC PHARMA BALANCE SHEET DATA
Current assets Rs m6,8766,3227,0158,90715,066 
Current liabilities Rs m5,3494,4164,4746,8417,674 
Net working cap to sales %10.412.513.610.123.5 
Current ratio x1.31.41.61.32.0 
Inventory Days Days6464616867 
Debtors Days Days5056546441 
Net fixed assets Rs m3,2613,7654,1765,9478,237 
Share capital Rs m377377377377377 
"Free" reserves Rs m3,2034,5826,2358,37415,416 
Net worth Rs m3,9505,0296,7568,84616,005 
Long term debt Rs m9497055221880 
Total assets Rs m10,51910,47812,17316,41224,594 
Interest coverage x7.115.232.7202.7255.2 
Debt to equity ratio x0.20.10.100 
Sales to assets ratio x1.41.51.51.31.3 
Return on assets %14.917.220.217.329.4 
Return on equity %32.932.934.932.044.9 
Return on capital %38.238.544.040.058.7 
Exports to sales %31.930.640.339.355.7 
Imports to sales %12.510.29.510.010.4 
Exports (fob) Rs m4,6804,6507,5028,08517,551 
Imports (cif) Rs m1,8321,5541,7652,0503,283 
Fx inflow Rs m4,7964,8027,7208,28417,811 
Fx outflow Rs m2,2752,1992,6283,1475,318 
Net fx Rs m2,5212,6035,0925,13712,493 
ALEMBIC PHARMA CASH FLOW
From Operations Rs m 1,418 2,648 2,400 1,718 9,304 
From Investments Rs m -564 -670 -811 -2,556 -3,105 
From Financial Activity Rs m -446 -2,288 -1,511 867 -1,959 
Net Cashflow Rs m 408 -310 79 29 4,240 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 74.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 2.9%
FIIs 9.1%
ADR/GDR 0.0%
Free float 13.9%
Shareholders 49,328
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Alembic Road, ,Vadodara,Gujarat - 390 003
E-MAIL apl.investors@alembic.co.in WEB www.alembic-india.com
TELEPHONE (0265) 2282 550 FAX (0265) 2282 506
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, B-102-103, Shangrila Complex, Akota, Vadodara-20
AUDITOR K. S. Aiyar & Co.
CHM: Chirayu R. Amin (MD) COMP SEC: Rajkumar Baheti YEAR OF INC: 2010 BSE CODE: 533573 FV (Rs): 2 DIV YIELD (%): 0.8

More Pharmaceuticals Company Fact Sheets:   VENUS REMEDIES  SUVEN LIFE  NOVARTIS  ALEMBIC LTD  SUN PHARMA  

Compare ALEMBIC PHARMA With:   VENUS REMEDIES  SUVEN LIFE  NOVARTIS  ALEMBIC LTD  SUN PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day Flat; Pharma Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day flat.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - MYLAN COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS